# A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

> **NCT03571568** · PHASE1,PHASE2 · RECRUITING · sponsor: **BioInvent International AB** · enrollment: 140 (estimated)

## Conditions studied

- Indolent B-Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** BI-1206
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Acalabrutinib

## Key facts

- **NCT ID:** NCT03571568
- **Lead sponsor:** BioInvent International AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-05-16
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03571568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03571568, "A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03571568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*